---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-154009"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:22:23.772451+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics to merge with Obsidian in all-stock deal backed by $350M PIPE

## Summary
- Galera and Obsidian to merge under new parent; Galera shareholders get ~1.8% of combined co plus CVRs.
- Obsidian shareholders get ~53.2%; $350M PIPE investors get ~45% of combined company.
- Galera valued at $13.8M (net cash $1.8M), Obsidian at $413.5M; closing conditions include S-4 effectiveness.
- Galera legacy assets (tilarganine, avasopasem, rucosopasem) subject to CVR payout to Galera common holders.
- Insider support: 51.1% Galera holders and 62.8% Obsidian holders agree to vote in favor.

## SEC filing metadata
- accession: 0001193125-26-154009
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312526154009/0001193125-26-154009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312526154009/d124753d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-154009
- JSON: https://secwatch.observer/filing/0001193125-26-154009.json
- Plain text: https://secwatch.observer/filing/0001193125-26-154009.txt

## Source-grounded claims
- claim_id: 6a1930080d6267a5303e86cdeef28b88addd8066
  claim: Galera Therapeutics, Inc. entered into Agreement and Plan of Merger with Obsidian Therapeutics, Inc., Gazelle Parent, Inc., Onyx MergerSub, Inc., Gazelle Merger Subsidiary, Inc. (effective 2026-04-14).
  evidence_excerpt: On April 14, 2026, Galera Therapeutics, Inc., a Delaware corporation (“Galera”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Galera, Obsidian Therapeutics, Inc., a Delaware corporation (“Obsidian”), Gazelle Parent, Inc., a Delaware corporation (“Parent”), Onyx MergerSub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Obsidian Merger Sub”), and Gazelle Merger Subsidiary, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Galera Merger Sub”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312526154009/0001193125-26-154009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.